CN1133172A - Powdered preparation for treating wounds and lesions - Google Patents
Powdered preparation for treating wounds and lesions Download PDFInfo
- Publication number
- CN1133172A CN1133172A CN 93121523 CN93121523A CN1133172A CN 1133172 A CN1133172 A CN 1133172A CN 93121523 CN93121523 CN 93121523 CN 93121523 A CN93121523 A CN 93121523A CN 1133172 A CN1133172 A CN 1133172A
- Authority
- CN
- China
- Prior art keywords
- wound
- medicine
- gram
- day
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010052428 Wound Diseases 0.000 title abstract description 46
- 208000027418 Wounds and injury Diseases 0.000 title abstract description 46
- 238000002360 preparation method Methods 0.000 title description 3
- 230000003902 lesion Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 29
- 230000035876 healing Effects 0.000 claims abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 239000001814 pectin Substances 0.000 claims description 10
- 229920001277 pectin Polymers 0.000 claims description 10
- 235000010987 pectin Nutrition 0.000 claims description 10
- 229940088710 antibiotic agent Drugs 0.000 claims description 7
- 229940035674 anesthetics Drugs 0.000 claims description 5
- 239000003193 general anesthetic agent Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000009172 bursting Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 abstract description 11
- 231100000397 ulcer Toxicity 0.000 abstract description 11
- 210000000981 epithelium Anatomy 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 7
- 238000005469 granulation Methods 0.000 abstract description 4
- 230000003179 granulation Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 208000035415 Reinfection Diseases 0.000 abstract 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000001126 granulation tissue Anatomy 0.000 description 7
- 208000033809 Suppuration Diseases 0.000 description 6
- 239000000416 hydrocolloid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- XBCXJKGHPABGSD-UHFFFAOYSA-N methyluracil Natural products CN1C=CC(=O)NC1=O XBCXJKGHPABGSD-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 3
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 3
- 229950002569 trimecaine Drugs 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- -1 acetyl homosulfamine Chemical compound 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- AUJXLBOHYWTPFV-UHFFFAOYSA-N levomycin Chemical compound CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the medicine for curing the infectious and slowly healing wound and ulcer, the composition ingredients are as follows: antibacterial agent 0.1-2.0g, accelerator for restoing health 2.0-4.0g, sugar 2.8-8g, pectine adding to 100g. Said invention is of very fine powdery external medicine which is applied on the surface of the wound to form a water-gel covering layer which ensures the slow release of medicine and the best exchange of air and moisture and prevents reinfection. Said medicine can accelerate the growth and mature of granulation and epithelium, so that it can promote the wound healing.
Description
The present invention relates to field of medicaments and promptly relate to the wound for the treatment of infected difficult healing and the external used medicine of ulcer.
At present wound that causes because of the various causes of disease for treatment and ulcer medicine for external use commonly used are that (form has granule for hydrocolloid preparation on natural polysaccharide and synthetic polymer basis, gel, plaster), for example the hydrocolloid of U.S. Squibb company is by 20% gelatin, 20% pectin and 20% sodium carboxymethyl cellulose (CMC-Na) (1,2,3,4) form, the hydrocolloid preparation of Denmark ColoplastAG company is by CMC-Na, and hemicellulose and modified cellulose are formed.
On the basis of these hydrocolloids, produce following various forms of compositions: Granu-flex; Varihesive DuoDerm; DuoDerm Granulat; Varihesive Granu-lat; Comfeel Ulcus PuPer; Comfeel Pastc (6).
Said medicine effectively (is the regeneration or the hypertrophy of granulation tissue, forms and the maturation period) treatment wound second stage.But invalid to the treatment infected wound, must replenish antibacterials and use special treatment method, make therapeutic process complicated and reduced its curative effect (7) like this.
Be wound and the ulcer that convenient treatment is infected, the normal recently complex composition that uses, it includes antibacterials, anesthetics, rehabilitation promoter is such as Diokcekol, lebocin, lebomekol.In the above-mentioned composition by the constituent and the project of being applied for the most close be Diokcekol ointment, the latter is contained antiseptic Diokcitin-1 gram, anesthetics trimecaine-4 gram, accelerator for concrescence methyl uracil-4 gram, polyethylene glycol oxide (PAO) 1500-18.2 gram, (PAD) 400-728 gram (prototype) (8), similarly medicine demonstrates antibiotic and sterilization and clean wound effect, but their shortcoming is to promote that the effect of agglutination is very weak.
Purpose of the present invention is exactly that creation is a kind of to treating infected that the various causes of disease cause, the wound of long-term disunion and the efficient medicine of ulcer.
Meeting above-mentioned purpose is a kind of very thin powdery compound formulation, and its composition comprises antibacterials, anesthetis, and rehabilitation promoter, sugar, pectin etc., and form in following ratio:
Antimicrobial drug 0.1-2.0 gram
Anesthetis 2.0-4.0 gram
Rehabilitation promoter 3.0-8.0 gram
Sugar 20-30 gram
Pectin adds to 100 grams
Pectin and sugar generally as inserts to improve dissolubility and to have gelling properties, in the present invention as adjuvant to reach other purposes.
Cause brand-new character promptly agglutination to be had very high facilitation with certain proportion and medicinal component combination material here.
The effect that obtains healing ahead of time be for expect and also can not be simply decide with the comprehensive function of medicinal each component.
Repertoire is crushed to the powder of superfine color and outward appearance homogeneous and is prepared into medicine.This medicine can be sprinkling upon fresh, on the wound surface and ulcer of infected and long-term not healing; Also can be used for because of nutrition reason and radio-induced ulcer.
When medicine is put into wound surface, form sticking hydrocolloid cover layer, medicine is slowly discharged hindering face,, prevent subinfection again for wound healing provides best physicochemical condition (aqueous vapor exchange).
Antibacterials adopt suppurative wound are infected effective broad-spectrum antibiotic: levomycetin for example, gentamycin, acetyl homosulfamine etc.
Rehabilitation promoter is adopted is some medicines that can promote rehabilitation course when using in the part.For example: methyl uracil, achemin etc.
Anesthetis uses is that some can have anesthetic action when using in the part, procaine for example, trimecaine, lignocaine etc.
With drug regimen, the medicine that is prepared into like this can reach therapeutic effect to greatest extent on the basis of hydrocolloid.
Antibacterial activity did not strengthen when the antibacterial activity of medicine was limited the quantity of with regard to reducing, being higher than maximum when the antibacterials consumption was lower than limiting the quantity of of regulation, and side effect has strengthened.
Anesthetics content is lower than regulation and causes drug effect significantly to reduce when limiting the quantity of, and is higher than when limiting the quantity of at most that anaesthetic effect does not improve and side effect increases.
Cause the medicine regeneration to descend under rehabilitation promoter is lower than in limited time, also can not strengthen rehabilitation course in limited time above last.
Sugar and dosage of pectin all can make during for upper and lower limit medicine be bonded in the wound top layer well and guarantee the condition (aqueous vapor exchange) of necessity to be provided and to guarantee tectal adsorption property for healing ahead of time.
Embodiment 1
With rat with etherization after; area of formation is 3 square centimeters a circular deep layer wound on its scapula; on wound, sew on a ring with the restriction wound contraction; the sheet with holes of ring upper cover last layer protectiveness; two days later; throw off sheet when developing into the suppuration pathological changes, at this moment can observe a lot of secretions, the serosity of suppuration is arranged in the wound.Remove secretions, clean wound, make it cover in wound surface fully through applying " Diokcekol " medicine (prototype) at wound above the annulus with normal saline.
After one day wound surface is carried out similar processing until healing fully.At the 7th day ring is taken off, cover on the wound that " Diokcekol " handled, to prick to bandage again with deposited paper afterwards and treat.
Result of the test shows that suppuration process to the just was through with in five days.Do not observe suppuration secretions and perilesional inflammation again.Not had antibacterial at the 7th day by the wound of bacterial infection exists.
Cytolgical examination in ointment finds that neutrophil cell reduces, the effect of macrophage strengthens, but fibroblastic increase does not appear, what adapt therewith is that granulation tissue slowly grows into the one-tenth bark that can be observed granulation tissue in 14 days and the formation of edge epithelium, this moment, wound surface was 1.8 square centimeters, heal fully to the 23rd day wound, but that is that all right is ripe from the morphology conjunctive tissue, and the thickness of epidermis yet is lower than standard.
Embodiment 2
The processing mode of wound is with embodiment 1.Two days later, on wound, sprinkle the medicated powder that skim is made up of following component.
Levomycin 2.0 grams
Trimecaine 3.5 grams
Methyl uracil 6.0 grams
Sugar 28.0 grams
Pectin is added to 100 grams
Do not observe suppurative inflammation by the 5th day.Can be observed penetrating fluid, apply with sheet with holes and cover wound, the granulation of red slight bleeding occurred.Aseptic in fact to the 7th day wound, from the cytology, a large amount of macrophages and fibroblast and poly plumule are arranged on the neutrophil cell quantity background seldom in ointment.Be full of smooth sophisticated granulation and can be observed the formation of active epithelium to the 10th day wound.Finding in ointment has epithelial cell, reaches 0.8 square centimeter to the 14th day wound area, and whole healings were seen from morphology and sophisticated conjunctive tissue occurred at the 23rd day and meet normal multiwalled smooth epithelium by about the 18th day.
Embodiment 3
The processing method of wound sprinkles the medicine that skim is made up of following ingredients to wound two days later with embodiment 1.
Gentamycin 0.2 gram
Lignocaine 2.0 grams
Achemin 7.0 grams
Sugar 25.0 grams
Pectin is added to 100.0 grams
Be eased to the 5th day suppuration process, the exudate amount reduces, and covers the fiber compress on wound, and wound surface produces granulation tissue.Aseptic to the 7th day wound reality, see that from the cytology macrophage content is very high the secretions of wound, neutrophil cell is a small amount of, and fibroblast reduces and unique multilamellar plumule, the granulation tissue layer that is flattened at the 10th day wound covers and the edge has epithelium to form, reach 1.0 square centimeters to the 14th day wound, at the 20th day, healing fully.See the 23rd day conjunctive tissue from morphology to be in the maturation period that the thickness of epithelium is near normal.
Embodiment 4
The medicine composition is as follows:
Diokcitin 1.0 grams
Trimecaine 3.6 grams
Methyl uracil 4.0 grams
Sugar 20.0 grams
Pectin to 100 gram
Be applied to treat the patient of one group of acra ulcer, very high clinical efficacy is arranged.Purpose is to promote the formation (the acra ulcer patient that long-term bed causes, diabetes patient etc.) of wound surface granulation and epithelium.
Clinical data:
Patient, the woman, 45 years old, give birth to and A.13 tie up this Nevski surgery institute's wound and the diagnosis and treatment of traumatic infection material, suffer from diabetes I type, be in a bad way, the left foot toes suppurate downright bad, consider the PBF that still keeps suitable, and the sign of undirected shank development inflammation, amputation is not done in decision, save lower limb, treat wound surface bacterioscopy during beginning from the measure that transfer medicine of the present invention with binder on March 2,21 days to 1992 January in 1992, the enterococcus number is 2.8 * 100000, treats the 3rd day bacterial population and reduces to below 1000.Antibacterial in every gram wound tissue is less than 10.Cytolgical examination, to using Drug therapy of the present invention the 3rd day, cytosis appears, illustrate that the tissue regeneration process produces, the epithelial number of plies increases to 6 by 3, and fibrocyte increases to 12 by 2, by the tenth day that treats, the foundation of this process is more obvious, and no matter from clinical or cytological angle, sophisticated sign all appears activating in granulation tissue and edge epithelium.The wound area is from 6 * 4 centimetres
2Be reduced into 0.5 * 0.3 centimetre
2
By above-mentioned clinical observation as seen: not only can avoid the amputation that disables, and serious suppuration process is stopped fully until wound healing.
On from last visible medicine of the present invention from antibiotic anti-infectious function no less than the prototype medicine, thereby growth and the ripe ability of wound healing that promotes of quickening granulation tissue and epithelium then obviously surpass the latter, medicine of the present invention is at the wound of the infected indolence of treatment, hemorrhoid, ulcer trophism, radioactive all has very successful clinical effectiveness.
Claims (1)
1. be used for the treatment of the medicine of the wound of infected difficult healing and the intestinal of bursting, it comprises antibacterials, anesthetics and rehabilitation promoter, and it is characteristics with superfine powder, is adjuvant with pectin and sugar, constituent is as follows:
Antibacterials 0.1-2.0 gram
Anesthetics 2.0-4.0 gram
Rehabilitation promoter 3.0-8.0 gram
Sugar 20-30 gram
Pectin adds to 100 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93121523 CN1133172A (en) | 1993-12-30 | 1993-12-30 | Powdered preparation for treating wounds and lesions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93121523 CN1133172A (en) | 1993-12-30 | 1993-12-30 | Powdered preparation for treating wounds and lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1133172A true CN1133172A (en) | 1996-10-16 |
Family
ID=4993723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93121523 Pending CN1133172A (en) | 1993-12-30 | 1993-12-30 | Powdered preparation for treating wounds and lesions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1133172A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252335B2 (en) * | 2006-03-21 | 2012-08-28 | Maraccini Philip A | Healing powder and method of use thereof |
| CN113769103A (en) * | 2021-10-11 | 2021-12-10 | 中山大学 | Mesenchymal stem cell preparation for treating diabetic skin ulcer and preparation method thereof |
-
1993
- 1993-12-30 CN CN 93121523 patent/CN1133172A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252335B2 (en) * | 2006-03-21 | 2012-08-28 | Maraccini Philip A | Healing powder and method of use thereof |
| CN113769103A (en) * | 2021-10-11 | 2021-12-10 | 中山大学 | Mesenchymal stem cell preparation for treating diabetic skin ulcer and preparation method thereof |
| CN113769103B (en) * | 2021-10-11 | 2023-12-05 | 中山大学 | Mesenchymal stem cell preparation for treating diabetic skin ulcers and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gilchrist et al. | Wound treatment with Sorbsan—an alginate fibre dressing | |
| CA2409076C (en) | Composition and method for growing, protecting, and healing tissues and cells | |
| US8168599B2 (en) | Composition and method for healing tissues | |
| AU2006318655B2 (en) | Compositions for disrupting and inhibiting reconstitution of wound biofilm | |
| CN1850291A (en) | Liquid wound-dressing with functions of promoting heal of wound and bacterial-resisting | |
| US20050208114A1 (en) | Composition and method for healing tissues | |
| US20060120993A1 (en) | Treatment of lesions of the soft tissues | |
| Sonar et al. | A comprehensive review on wound dressing usage in clinical settings | |
| RU2193896C2 (en) | Covering for wounds | |
| CN111166932B (en) | Liquid wound spray dressing and preparation method thereof | |
| CN1133172A (en) | Powdered preparation for treating wounds and lesions | |
| CN116474154B (en) | Hydrogel dressing band-aid for diabetic wounds and its application | |
| CN110251716B (en) | Gel dressing for wound care and preparation method thereof | |
| CN116077707A (en) | Collagen sponge dressing and preparation method thereof | |
| CN1259052C (en) | Medicinal composition for treating burn and scald and preparing method | |
| CN1317042C (en) | Biologic external application medicine for curing wound | |
| RU2054924C1 (en) | Preparation for treatment of infected slaggish-healing wound and ulcer | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
| CN1199666C (en) | Medicine 'Suyusan' for treating intractable ulcer | |
| Williams | Tegagen alginate dressing for moderate to heavily exuding wounds | |
| CZ305405B6 (en) | Use of combination comprising polymeric absorbent and non-metabolizable sugar for promoting cell reconstruction and/or cell differentiation | |
| CN1258367C (en) | Medicine for treating trauma | |
| RU2115436C1 (en) | Agent for wound treatment | |
| Topham | Sugar paste and povidone-iodine in the treatment of wounds | |
| CN1036700C (en) | Jelly for curing musosa diseases and pathological changes of fore-cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication |